InterAx Biotech SA

InterAx Biotech AG is a research-based Swiss company, spin-off from the ETH Zürich and the Paul Scherrer Institute (PSI). Our core expertise resides in the combination of cell-based real-time assays, including IP-protected biosensors, and proprietary big data analysis methods for the selection of the best drug molecules. InterAx has secured a seed-investment from Boston-based Biotech investors and has recently achieved an important milestone that triggered an additional cash inflow.

InterAx has established a novel GPCR lead discovery platform that efficiently delivers lead compounds that are hallmarked by confined cellular signaling profiles. This results in molecules with high efficacy and reduced adverse events. Our GPCR platform is unrestricted to a GPCR target, indication or type of compound, e.g. biologics or small molecules.

The InterAx discovery platform currently consists of three core assets: Virtual screening, state-of-the-art signaling assays including IP-protected protein-based biosensors for drug-induced signaling analysis, and systems biology for identification of most informative drug screening assays and prediction of in vivo effects. This unique combination ensures a highly efficient process for the identification of novel GPCR lead compounds. The lean design of the platform allows to conduct in-house projects in an early R&D stage towards IP-protection of novel compounds.